Fei Chen and colleagues discuss the role of the tumor microenvironment (TME) in cancer progression, highlighting ways in which the TME can be targeted to improve therapeutic efficacy and reduce resistance in a personalized approach to cancer therapy.

As there has been limited success in the development of glycoprotein tumor markers, Eleftherios Diamandis and colleagues review the challenges, and discuss how new technology will facilitate quantification of these biomarkers for clinical use.